Friday 6 November 2026 Export CELZ’s income statement to Excel — free account

Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,000.00, down 45.5% from fiscal 2024.

Revenue: 0.00%
EPS: +14.6%
Free cash flow: −27.1%

Quarter to June 2026, against a year earlier

0.62 0.01 +1.64%

Follow CELZ

Alert me

Market cap: $4.0M
P/E: 0.0×
Fwd P/E: −0.6×
Dividend yield: —
F-score: 4/9
Altman Z: −4.32
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 4.00

Revenue ttm 0.02

Net income ttm (6.04)

Free cash flow ttm (5.90)

Net debt Q (8.84)

Valuation

P/E 0.00

Forward P/E (0.56)

Price / sales 135.00

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.26

Financial health

Current ratio Q 12.91

Debt / equity Q 0.00

Interest coverage Q 30.69

Growth

Revenue growth Q 0.00%

Operating income growth Q −23.64%

EPS, this year +53.17%

EPS, next year A +25.42%

Revenue, next year A +1,001,233.33%

EPS, past 5 yrs —

EPS, next 5 yrs A +30.39%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 43.14%

10-year low 10-year high

P/B against its own 10 years 5.42%

10-year low 10-year high

EV/FCF against its own 10 years 74.10%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	10	6	7	9
Receivables	—	—	—	—
Inventory	0	0	—	—
Other	—	—	—	—
	10	6	7	9

	2023	2024	2025	Q'26
Payables	0	0	0	1
ST’ Debt	—	—	—	—
Other	0	0	0	0
	0	0	0	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	(48.43%)	(59.24%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	65.27%	0.00%	(22.01%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.39 Actual −0.41

−0.88 −0.70 −0.52 −0.34 −0.16

Q3 FY25 Met 0.00

Q4 FY25 Miss −0.43

Q1 FY26 Beat +0.01

Q2 FY26 Miss −0.02

Q3 FY26 — Nov 6

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.48	−0.48	Met by 0.00
Q4 FY25	−0.37	−0.80	Miss by 0.43
Q1 FY26	−0.39	−0.38	Beat by 0.01
Q2 FY26	−0.39	−0.41	Miss by 0.02
Q3 FY26	−0.24	—	Reports 6 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.38)	(0.41)	—	—	—
’25	(0.83)	(0.48)	(0.48)	(0.80)	(2.52)
’24	(0.73)	(1.11)	(0.75)	(1.12)	(3.71)
’23	(0.70)	(0.78)	(1.02)	(1.21)	(3.76)
’22	(1.79)	(1.99)	(0.70)	(5.30)	(9.30)
’21	111.84	(12.52)	(7.52)	(32.66)	59.13
’20	0.05	(0.11)	1.45	(628.77)	(627.38)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	—	—	0	0
’24	—	0	—	0	0
’23	—	—	0	0	0
’22	0	—	0	0	0
’21	—	0	0	0	0
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(1)	(1)	(2)	(6)
’24	(1)	(1)	(1)	(2)	(5)
’23	(4)	(1)	(1)	(2)	(8)
’22	(2)	(2)	(1)	(4)	(8)
’21	0	0	0	(1)	(2)
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(1)	(1)	(2)	(6)
’24	(1)	(1)	(1)	(2)	(6)
’23	(4)	(1)	(1)	(2)	(8)
’22	(2)	(2)	(6)	(4)	(8)
’21	0	0	0	(1)	(2)
’20	0	0	0	0	(1)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	0	0	0	0	0	0	0	0	0	0		+2.8%	60	60	60	+2,055.4%
	Gross margin, %	0.00	(66.67)	43.41	72.51	69.24	45.33	67.83	60.00	60.00	63.33	61.18		+63.3 pt	Powerpack Creative Medical Technology Holdings, Inc.’s next three years, line by line Analysts expect revenue to grow 2,055.4% a year to 2028 — faster than the 2.8% of the last 8 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(1)	(3)	(14)	(8)	(36)	19	(10)	(5)	(5)	(6)	(6)		+25.7%
	EBT margin, %	0.00	(55,397.92)	(10,977.25)	(5,126.10)	(22,082.19)	21,881.32	(11,449.21)	(58,740.00)	(49,940.91)	(99,916.67)	0.00		(99,916.7) pt
	Net income	(1)	(3)	(14)	(8)	(36)	19	(10)	(5)	(5)	(6)	(6)		+25.7%
Per share, $
Per share, $	Revenue	0.00	0.00	0.32	0.16	2.84	0.34	0.08	0.01	0.01	0.00	0.00		n/m
	Earnings	(0.08)	(0.25)	(34.96)	(8.20)	(627.38)	73.75	(9.30)	(3.76)	(3.71)	(2.52)	(2.07)		+46.4%
	Cash flow	(0.05)	(0.08)	(2.69)	(1.17)	(7.51)	(8.51)	(7.13)	(5.70)	(3.58)	(2.46)	(1.59)		+55.1%
	Capex	0.00	0.00	0.00	0.00	(4.32)	0.00	0.00	(0.07)	(0.14)	0.00	0.00		n/m
	Free cash flow	(0.05)	(0.08)	(2.69)	(1.17)	(11.82)	(8.51)	(7.13)	(5.77)	(3.72)	(2.46)	(1.59)		+54.7%
	Book value	(0.02)	(0.21)	(10.23)	(7.80)	(687.44)	39.22	14.51	7.35	4.28	3.16	2.34		n/m
	Shares, m	9	11	0	1	0	0	1	1	1	2	3		(14.1%)
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.30	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	0.00	23,313.55	1,406.15	48.92	54.67	26.00	78.39	170.99	274.72	135.00		2,819.3
	P/B	—	0.00	0.00	0.00	0.00	0.56	0.26	0.63	0.54	0.62	0.26		0.3
	EV/Sales	—	0.00	23,316.59	1,412.04	53.13	(46.05)	(26.44)	(41.09)	(120.12)	(142.33)	(377.99)		2,711.7
	EV/FCF	—	(107,567.26)	(2,756.42)	(192.64)	(11.00)	1.88	0.31	0.25	0.23	0.22	0.57		(12,280.5)
Cash, $m
Cash, $m	Operating cash flow	0	(1)	(1)	(1)	0	(2)	(8)	(8)	(5)	(6)	(6)		+33.2%
	Capex	0	—	—	—	0	—	—	0	0	—	(5)		+45.4%
	Free cash flow	0	(1)	(1)	(1)	(1)	(2)	(8)	(8)	(6)	(6)	(6)		+32.8%
Balance, $m
Balance, $m	Working capital	0	(2)	(4)	(9)	(40)	10	15	10	6	7	8		n/m
	Net debt	0	0	0	1	1	(11)	(8)	(10)	(6)	(7)	(9)		+61.9%
	Shareholders’ equity	0	(2)	(4)	(8)	(40)	10	16	10	6	8	9		n/m
Returns, %
Returns, %	ROA	(411.77)	(1,011.83)	(4,014.61)	(1,683.27)	(5,818.55)	320.57	(66.62)	(35.36)	(63.20)	(82.81)	(73.30)		+329.0 pt
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(84.87)	(984.74)	(895.02)	(1,213.03)	0.00		(1,213.0) pt
	ROE	1,414.77	222.15	438.12	140.55	151.73	(129.86)	(77.78)	(40.34)	(65.85)	(86.53)	(77.91)		(1,501.3) pt
People
People	Employees	—	—	—	—	—	5	4	5	4	4	—		(5.4%)
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.02	0.02	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADTX Aditxt, Inc.	$4.4M	— (loss-making)	—	+1,120.00% (above 0%: growing)	n/m	+60.82% (above 0%: growing)	23.77%	(35,753.28%)	Compare
AZTR Azitra, Inc.	$4.4M	1.3×	— (loss-making)	−93.38% (below 0%: shrinking)	n/m	−19.55% (below 0%: shrinking)	100.00%	0.00%	Compare
XBIO Xenetic Biosciences, Inc.	$4.4M	— (loss-making)	— (loss-making)	+11.99% (above 0%: growing)	n/m	−128.11% (below 0%: shrinking)	100.00%	(147.09%)	Compare
OSRH OSR Health, Inc.	$4.1M	— (loss-making)	—	−72.20% (below 0%: shrinking)	n/m	−398.76% (below 0%: shrinking)	27.43%	(960.69%)	Compare
NCNA NuCana PLC Sponsored ADR	$4.0M	— (loss-making)	—	—	n/m	+55.66% (above 0%: growing)	0.00%	0.00%	Compare
PMCB Nuvilex Inc.	$4.0M	— (loss-making)	—	−103.94% (below 0%: shrinking)	n/m	+60.84% (above 0%: growing)	100.00%	0.00%	Compare
CELZ Creative Medical Technology Holdings, Inc.	$4.0M	— (loss-making)	— (loss-making)	0.00%	n/m	−27.05% (below 0%: shrinking)	66.67%	0.00%
DRMA Dermata Therapeutics, Inc.	$3.8M	— (loss-making)	—	—	n/m	+9.99% (above 0%: growing)	0.00%	0.00%	Compare
CVKD Cadrenal Therapeutics, Inc.	$3.6M	— (loss-making)	—	—	n/m	+26.24% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$4.1M	—	—	−72.20%	—	+18.12%	25.60%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 14 July 2026

Ownership

Directors and executive officers, together 1.00%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Creative Medical Technology Holdings, Inc. (CELZ) Latest News

20 Oct

Impact 4 · 9:15 AM · GlobeNewswire

Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study

17 Sep

Impact 3 · 9:00 AM

Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing

20 Aug

Impact 4 · 9:15 AM

Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning

6 Aug

Impact 4 · 11:04 AM · InvestorsHub

Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy

Impact 3 · 9:15 AM

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

22 Jun

Impact 4 · 9:15 AM · GlobeNewswire

Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain

16 Jun

Impact 3 · 3:49 PM · Proactive Investors

Creative Medical Technology opens nationwide burn-pit data registry

Impact 3 · 9:00 AM

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

28 Apr

Impact 5 · 9:01 AM · GlobeNewswire

Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies

9 Apr

Impact 3 · 6:56 AM · Simply Wall St.

Analysts Expect Breakeven For Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Before Long

10 Feb

Impact 4 · 9:00 AM · GlobeNewswire

Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline

13 Jan

Impact 4 · 9:15 AM · GlobeNewswire

Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

6 Jan

Impact 4 · 9:15 AM · GlobeNewswireInsider MonkeySimply Wall St.MT NewswiresInsider MonkeyZacksZacksInsider Monkey

Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative

17 Dec

Impact 4 · 9:15 AM

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

2 Dec

Impact 4 · 9:15 AM · GlobeNewswire

Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

5 Nov

Impact 4 · 9:55 AM · Zacks

Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now

30 Oct

Impact 4 · 9:15 AM · GlobeNewswire

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

29 Oct

Impact 3 · 9:00 AM

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

27 Oct

Impact 3 · 8:15 AM · GlobeNewswireInsider MonkeySimply Wall St.Simply Wall St.MT NewswiresSimply Wall St.Simply Wall St.Insider Monkey

Creative Medical Technology Holdings Issues Letter to Shareholders

7 Oct

Impact 4 · 9:15 AM · GlobeNewswire

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

13 Aug

Impact 4 · 9:01 AM

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain

31 Jul

Impact 4 · 5:43 AM · Zacks

New Strong Sell Stocks for July 31st

17 Jul

Impact 4 · 9:15 AM · GlobeNewswire

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

11 Jul

Impact 4 · 8:01 AM

Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling

27 Apr

Impact 3 · 9:41 AM · Simply Wall St.

Companies Like Creative Medical Technology Holdings (NASDAQ:CELZ) Are In A Position To Invest In Growth

20 Mar

Impact 4 · 7:50 AM · GlobeNewswire

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

16 Mar

Impact 4 · 10:14 AM · Simply Wall St.

Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) Shift From Loss To Profit

6 Mar

Impact 3 · 8:10 AM

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

20 Feb

Impact 4 · 8:00 AM · GlobeNewswire

Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential

14 Feb

Impact 4 · 7:00 AM

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Creative Medical Technology Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 14 July 2026

Ownership

Creative Medical Technology Holdings, Inc. (CELZ) Latest News

20 Oct

17 Sep

20 Aug

6 Aug

22 Jun

16 Jun

28 Apr

9 Apr

10 Feb

13 Jan

6 Jan

17 Dec

2 Dec

5 Nov

30 Oct

29 Oct

27 Oct

7 Oct

13 Aug

31 Jul

17 Jul

11 Jul

27 Apr

20 Mar

16 Mar

6 Mar

20 Feb

14 Feb

Stockrow Weekly